(Q33397918)

English

Multicenter, randomized study of genetically modified recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in cancer patients receiving chemotherapy

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Multicenter, randomized study of genetically modified recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in cancer patients receiving chemotherapy (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

thrombocytopenia

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Shikai Wu

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Yang Zhang

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Liyan Xu

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Yun Dai

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Yuee Teng

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Shanshan Ma

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Seong-Hyun Ho

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Jong-Mook Kim

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Seung Shin Yu

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sunyoung Kim

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Santai Song

11

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

publication date

1 November 2011

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Supportive Care in Cancer

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

20

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1875-1884

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Importance of predosing of recombinant human thrombopoietin to reduce chemotherapy-induced early thrombocytopenia

1 reference

https://api.crossref.org/works/10.1007%2FS00520-011-1290-X

21 January 2018

Risks, costs, and alternatives to platelet transfusions

1 reference

https://api.crossref.org/works/10.1007%2FS00520-011-1290-X

21 January 2018

Interleukin-11.

1 reference

https://api.crossref.org/works/10.1007%2FS00520-011-1290-X

21 January 2018

The cloning and biological characterization of recombinant human interleukin 11.

1 reference

https://api.crossref.org/works/10.1007%2FS00520-011-1290-X

21 January 2018

Thrombopoietic activity of recombinant human interleukin 11 (rHuIL-11) in normal and myelosuppressed nonhuman primates

1 reference

https://api.crossref.org/works/10.1007%2FS00520-011-1290-X

21 January 2018

Improvement of biological and pharmacokinetic features of human interleukin-11 by site-directed mutagenesis

1 reference

https://api.crossref.org/works/10.1007%2FS00520-011-1290-X

21 January 2018

Phase I/II dose escalation study of recombinant human interleukin-11 following ifosfamide, carboplatin and etoposide in children, adolescents and young adults with solid tumours or lymphoma: a clinical, haematological and biological study

1 reference

https://api.crossref.org/works/10.1007%2FS00520-011-1290-X

21 January 2018

Incidence, cost, and outcomes of bleeding and chemotherapy dose modification among solid tumor patients with chemotherapy-induced thrombocytopenia

1 reference

https://api.crossref.org/works/10.1007%2FS00520-011-1290-X

21 January 2018

Thrombocytopenia caused by the development of antibodies to thrombopoietin

1 reference

https://api.crossref.org/works/10.1007%2FS00520-011-1290-X

21 January 2018

Pharmacoeconomic analysis of oprelvekin (recombinant human interleukin-11) for secondary prophylaxis of thrombocytopenia in solid tumor patients receiving chemotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS00520-011-1290-X

21 January 2018

Recombinant human thrombopoietin: basic biology and evaluation of clinical studies

1 reference

https://api.crossref.org/works/10.1007%2FS00520-011-1290-X

21 January 2018

The use of second-generation thrombopoietic agents for chemotherapy-induced thrombocytopenia

1 reference

https://api.crossref.org/works/10.1007%2FS00520-011-1290-X

21 January 2018

Endogenous thrombopoietin serum levels during multicycle chemotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS00520-011-1290-X

21 January 2018

Eltrombopag for the treatment of chronic immune (idiopathic) thrombocytopenic purpura

1 reference

https://pubmed.ncbi.nlm.nih.gov/22041866

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hematopoietic, immunomodulatory and epithelial effects of interleukin-11.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22041866

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Recombinant human interleukin-11 directly promotes megakaryocytopoiesis in vitro

1 reference

https://pubmed.ncbi.nlm.nih.gov/22041866

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical efficacy of rhIL-11.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22041866

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Recombinant human interleukin-11 stimulates multilineage hematopoietic recovery in mice after a myelosuppressive regimen of sublethal irradiation and carboplatin.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22041866

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tolerability and side-effect profile of rhIL-11.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22041866

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Recombinant human interleukin-11 stimulates megakaryocytopoiesis and increases peripheral platelets in normal and splenectomized mice

1 reference

https://pubmed.ncbi.nlm.nih.gov/22041866

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chemotherapy-associated hematopoietic toxicity

1 reference

https://pubmed.ncbi.nlm.nih.gov/22041866

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interleukin-11: review of molecular, cell biology, and clinical use.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22041866

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22041866

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase I trial of recombinant human interleukin-11 (neumega rhIL-11 growth factor) in women with breast cancer receiving chemotherapy.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22041866

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Value of recombinant human thrombopoietin in the treatment of chemotherapy-induced thrombocytopenia in patients with solid tumor

1 reference

https://pubmed.ncbi.nlm.nih.gov/22041866

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00520-011-1290-X

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33397918&oldid=2195322168"